Active Biotech to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference

(Thomson Reuters ONE) -


Lund, Sweden, May 17, 2010 - Active Biotech (NASDAQ OMX Nordic: ACTI) is
scheduled to present today at the Rodman & Renshaw 6th Annual Global Healthcare
Conference at the Grosvenor House Hotel in London. During the presentation, an
update regarding Active Biotech's development programs will be provided.

The presentation will include the Phase III project laquinimod, a novel oral
immunomodulatory drug for the treatment of multiple sclerosis, which is licensed
to Teva Pharmaceutical Industries Ltd and TASQ, Active Biotech's prostate cancer
project which just recently concluded Phase II clinical studies. Also, the Phase
III renal cancer project ANYARA, the SLE project 57-57 and the pre-clinical ISI
project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to - www.activebiotech.com .

The presentation will take place today, May 17, at 11:45 am BST / 12:45 Central
European Time.


About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, as well as
ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further
key projects in clinical development comprise the three orally administered
compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please
visit www.activebiotech.com for more
information.



Active Biotech is required under the Securities Markets Act to make the

information in this press release public. The information was submitted for
publication at 08:30 a.m. CET on May 17, 2010.


Contacts:

Active Biotech AB
Göran Forsberg, VP Investor Relations & Business Development
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00


[HUG#1415355]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 17.05.2010 - 08:30 Uhr
Sprache: Deutsch
News-ID 20952
Anzahl Zeichen: 0

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 301 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech